Table 6.

Effect of Treatment on Risk of Loss of Visual Acuity Score of ≥15 Letters Coincident With Progression to Advanced AMD^*

	Participants in AMD Categories 3 and 4 (n = 2516)		Participants in AMD Category 3 (n = 1588)		Participants in AMD Category 4 (n = 928)
Treatment	OR (99% CI)	PValue	OR (99% CI)	PValue	OR (99% CI)	PValue
Antioxidants vs no antioxidants	0.82 (0.63–1.06)	.04	0.87 (0.60–1.26)	.34	0.76 (0.53–1.11)	.06
Zinc vs no zinc	0.77 (0.60–1.00)	.011	0.87 (0.60–1.26)	.34	0.69 (0.47–0.99)	.009
Antioxidants vs placebo	0.79 (0.55–1.13)	.09	0.87 (0.52–1.46)	.49	0.71 (0.43–1.17)	.08
Zinc vs placebo	0.75 (0.53–1.07)	.04	0.87 (0.52–1.46)	.49	0.64 (0.38–1.06)	.02
Antioxidants + zinc vs placebo	0.63 (0.44–0.92)	.001	0.76 (0.45–1.30)	.19	0.52 (0.31–0.89)	.002
Total No. of participants with events	585		270		315

^*Unadjusted analysis by repeated-measures logistic regression. AMD indicates age-related macular degeneration; OR, odds ratio; and CI, confidence interval. P≤.01 is considered statistically significant.